133 related articles for article (PubMed ID: 32428732)
1. CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies.
Jaiswal SR; Bhakuni P; Aiyer HM; Soni M; Bansal S; Chakrabarti S
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1469-1476. PubMed ID: 32428732
[TBL] [Abstract][Full Text] [Related]
2. Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects.
Jaiswal SR; Chakraborty S; Lakhchaura R; Shashi P; Mehta A; Soni M; Chakrabarti S
Transplant Cell Ther; 2021 Feb; 27(2):144-151. PubMed ID: 33830023
[TBL] [Abstract][Full Text] [Related]
3. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
Jaiswal SR; Bhakuni P; Bhagwati G; Aiyar HM; Chakrabarti A; Chakrabarti S
Transplantation; 2020 Jan; 104(1):e23-e30. PubMed ID: 31478993
[TBL] [Abstract][Full Text] [Related]
4. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.
Bolaños-Meade J; Cooke KR; Gamper CJ; Ali SA; Ambinder RF; Borrello IM; Fuchs EJ; Gladstone DE; Gocke CB; Huff CA; Luznik L; Swinnen LJ; Symons HJ; Terezakis SA; Wagner-Johnston N; Jones RJ; Brodsky RA
Lancet Haematol; 2019 Apr; 6(4):e183-e193. PubMed ID: 30878319
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up of Abatacept, Post-Transplantation Cyclophosphamide, and Sirolimus-Based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases.
Jaiswal SR; Agarwal M; Bhagawati G; Das BC; Baligar P; Garg M; Biswas S; Chakrabarti S
Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38490295
[TBL] [Abstract][Full Text] [Related]
6. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
7. CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies.
Jaiswal SR; Bhakuni P; Bhagawati G; Aiyer HM; Soni M; Sharma N; Jaiswal RR; Chakrabarti A; Chakrabarti S
Bone Marrow Transplant; 2021 Jan; 56(1):185-194. PubMed ID: 32704091
[TBL] [Abstract][Full Text] [Related]
8. Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease.
Bhat DK; Olkhanud PB; Gangaplara A; Seifuddin F; Pirooznia M; Biancotto A; Fantoni G; Pittman C; Francis B; Dagur PK; Saxena A; McCoy JP; Pfeiffer RM; Fitzhugh CD
Front Immunol; 2021; 12():757279. PubMed ID: 34917079
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
10. Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation.
Jaiswal SR; Singhal P; Thatai A; Bhagwati G; Aiyer HM; Chakrabarti A; Chakrabarti S
Ann Hematol; 2020 Apr; 99(4):839-845. PubMed ID: 32025839
[TBL] [Abstract][Full Text] [Related]
11. T cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia.
Jaiswal SR; Bhakuni P; Zaman S; Bansal S; Bharadwaj P; Bhargava S; Chakrabarti S
Transpl Immunol; 2017 Aug; 43-44():54-59. PubMed ID: 28802588
[TBL] [Abstract][Full Text] [Related]
12. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
13. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant myeloid and immune suppression, reduced toxicity conditioning with posttransplant cyclophosphamide: Initial outcomes of novel approach for matched unrelated donor hematopoietic stem cell transplant for hemoglobinopathies.
Kharya G; Bakane AN; Rauthan AM
Pediatr Blood Cancer; 2021 Apr; 68(4):e28909. PubMed ID: 33470527
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
16. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors.
Nakamae H; Fujii K; Nanno S; Okamura H; Nakane T; Koh H; Nakashima Y; Nakamae M; Hirose A; Teshima T; Hino M
Transpl Int; 2019 Dec; 32(12):1322-1332. PubMed ID: 31432532
[TBL] [Abstract][Full Text] [Related]
17. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
[TBL] [Abstract][Full Text] [Related]
18. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
19. CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study.
Jaiswal SR; Aiyer HM; Rawat G; Gera A; Chakrabarti S
Exp Hematol; 2019 Sep; 77():26-35.e1. PubMed ID: 31449833
[TBL] [Abstract][Full Text] [Related]
20. HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Pawlowska AB; Cheng JC; Karras NA; Sun W; Wang LD; Bell AD; Gutierrez L; Rosenthal J
Biol Blood Marrow Transplant; 2018 Jan; 24(1):185-189. PubMed ID: 28939451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
